# Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

> **NCT00900627** · PHASE1,PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 330 (actual)

## Conditions studied

- Neoplasms
- Breast Neoplasms
- Breast Cancer

## Interventions

- **DRUG:** AZD8931
- **DRUG:** Paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00900627
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2012-04
- **Final completion:** 2015-02
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2016-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00900627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00900627, "Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00900627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*